Standard BioTools (LAB) AI Stock Analysis

• Market Cap: $451.99M
• Dividend Yield: N/A
• Average Volume (3M): 2.17M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.38
• Revenue Growth: 33.86%
• EPS Growth: 64.34%
• Country: US
• Employees: 814
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.07
• Shares Outstanding: 379,822,270
• 10 Day Avg. Volume: 4,016,920
• 30 Day Avg. Volume: 2,167,602
• PEG Ratio: >-0.01
• Price to Book (P/B): -1.12
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.98
• Enterprise Value/Market Cap: 0.25
• Enterprise Value/Revenue: 0.18
• Enterprise Value/Gross Profit: 1.42
• Enterprise Value/Ebitda: -0.24
• 1Y Price Target: $2.50
• Price Target Upside: 110.08% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 56 Neutral
• Price Target: $1.50 ▲(26.05%Upside)

Standard BioTools has a challenging financial position with significant leverage and ongoing losses, negatively impacting its overall score. However, recent corporate actions and strategic initiatives in proteomics offer potential for future growth. Technical analysis shows some positive short-term trends, but the valuation remains a concern due to persistent losses.

Positive Factors

Future Prospects

Signs of improvement on the horizon with positive customer trends, strengthening sales funnel, and momentum with SomaScan.

Operational Improvements

Solid operational expense controls showcase operational improvement despite a miss in gross margin due to mix and volume.

Revenue Performance

LAB reported 1Q revenue slightly better than consensus estimates, which is a good result in light of ongoing macro pressures and share weakness.

Negative Factors

Key Personnel Changes

The CFO departure (personal reasons) is a negative surprise though management is steadfast that key drivers (synergies, ILMN partnership) are unchanged.

Revenue Guidance

Disappointing initial 2025 revenue guidance of $165M-$175M vs. consensus of $186.9M, attributed to the proposed White House NIH spending cut.

Spending Environment

With a tepid spending environment and more meaningful commercial revenue from Illumina unlikely to occur until 2026, a downgrade to Sector Weight was issued.

Standard BioTools Business Overview & Revenue Model

Company Description

Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

How the Company Makes Money

Standard BioTools generates revenue primarily through the sale of its instruments and related consumables. The company's revenue model is based on a combination of one-time sales of its advanced systems and recurring sales of consumables and reagents required for ongoing experiments. Additionally, they offer software solutions that complement their hardware, creating opportunities for additional revenue streams. Key partnerships with academic institutions, research organizations, and pharmaceutical companies enhance their market reach and contribute to their earnings. Service contracts and maintenance agreements also provide a stable, recurring income source.

Standard BioTools Financial Statement Overview

Summary

Standard BioTools faces significant financial challenges, with persistent losses impacting profitability and cash flow. While the balance sheet is moderately stable due to a strong equity position, high leverage and negative cash flows pose risks. The company needs to address operational inefficiencies and improve revenue growth to achieve financial stability.

Income Statement

The company's income statement shows significant challenges with profitability. The TTM data reveals a negative net profit margin and declining revenue, indicating persistent losses. The gross profit margin is relatively stable but overshadowed by high operating losses, reflected in negative EBIT and EBITDA margins. Revenue growth is inconsistent, with recent periods showing a decline. These factors suggest difficulties in scaling operations profitably.

Balance Sheet

The balance sheet reflects a strong equity position with a positive equity ratio, but the company is highly leveraged, indicated by a significant debt-to-equity ratio. The return on equity is negative due to consistent net losses. However, cash reserves are healthy, partially offsetting the risks from high leverage. The overall balance sheet stability is moderate, with some financial risks due to the dependency on debt.

Cash Flow

The cash flow statement shows negative operating and free cash flows, indicating cash burn and potential liquidity issues. However, there is a notable improvement in cash flow from financing activities, bolstering cash reserves. The company struggles with converting revenue to cash, as seen in low ratios of cash flow to net income. The trajectory of cash flows suggests efficiency improvements are necessary to achieve sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	169.69M	174.43M	106.34M	97.95M	130.58M	138.14M
Gross Profit	79.81M	84.26M	50.45M	37.05M	69.37M	83.33M
EBITDA	-116.89M	-118.14M	-54.46M	-173.57M	-43.77M	-34.60M
Net Income	-132.76M	-138.88M	-74.66M	-190.10M	-59.24M	-53.02M
Balance Sheet
Total Assets	579.60M	612.34M	323.07M	390.31M	275.21M	324.76M
Cash, Cash Equivalents and Short-Term Investments	258.06M	292.87M	114.89M	165.78M	28.45M	68.52M
Total Debt	31.53M	33.00M	98.21M	102.66M	111.65M	95.38M
Total Liabilities	125.00M	140.62M	159.87M	471.78M	180.62M	185.71M
Stockholders Equity	454.60M	471.72M	163.20M	-81.47M	94.60M	139.05M
Cash Flow
Free Cash Flow	-123.89M	-151.81M	-46.12M	-93.19M	-57.33M	-28.13M
Operating Cash Flow	-111.26M	-143.45M	-43.29M	-89.37M	-44.06M	-15.42M
Investing Cash Flow	59.72M	363.17M	20.24M	-88.13M	-11.95M	39.98M
Financing Cash Flow	-82.93M	-102.62M	-6.81M	230.76M	15.96M	20.86M

Standard BioTools Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.19
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LAB, the sentiment is Positive. The current price of 1.19 is above the 20-day moving average (MA) of 1.10, above the 50-day MA of 1.11, and below the 200-day MA of 1.50, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 55.79 is Neutral, neither overbought nor oversold. The STOCH value of 38.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LAB.

Standard BioTools Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CSTL	73 Outperform	$587.55M	30.59	-1.20%	―	38.43%	86.19%
LAB	56 Neutral	$451.99M	―	-25.73%	―	33.86%	64.34%
PSNL	55 Neutral	$581.18M	―	-51.25%	―	15.57%	31.82%
OPK	52 Neutral	$1.05B	―	-3.04%	―	-13.79%	82.82%
FLGT	51 Neutral	$599.13M	―	-3.61%	―	1.71%	76.00%
Sector *	46 Neutral	C$190.36M	-4.25	-8.56%	3.09%	13.53%	-1.76%
MYGN	45 Neutral	$483.93M	―	-13.84%	―	7.38%	60.45%

Standard BioTools Corporate Events

Standard BioTools Sells Subsidiaries to Illumina

On June 22, 2025, Standard BioTools Inc. announced a strategic sale of its subsidiaries, including SomaLogic, to Illumina, Inc. for up to $425 million. This transaction aims to simplify Standard BioTools’ operations, achieve adjusted EBITDA break-even, and retain strategic upside through royalties and commercialization rights. The deal reflects improvements made to the business and aligns with the company’s focus on profitability and long-term value creation.

The most recent analyst rating on (LAB) stock is a Buy with a $2.75 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.

Standard BioTools Approves Equity Plan Amendment at Meeting

Standard BioTools Inc. held its 2025 Annual Meeting of Stockholders on June 18, 2025, where stockholders approved an amendment to the company’s Amended and Restated 2011 Equity Incentive Plan, increasing the number of shares of common stock reserved for issuance by 17,400,000 shares. Additionally, the election of Class III directors, approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm were also confirmed during the meeting.

The most recent analyst rating on (LAB) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.

Standard BioTools Q1 2025 Financial Results Overview

Standard BioTools reported its financial results for the first quarter of 2025, showing a revenue of $40.8 million, a 10% decrease from the previous year. Despite the revenue decline, the company achieved a 45% reduction in operating loss and a 29% improvement in adjusted EBITDA, attributed to cost reductions and productivity gains. The company maintains a strong balance sheet with $261 million in cash and no material debt. The strategic focus on proteomics and the upcoming launch of a new NGS-based product are expected to drive future growth.